Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

2.

Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB.

Hooper DC, Wolfson JS, Bozza MA, Ng EY.

Antimicrob Agents Chemother. 1992 May;36(5):1151-4.

3.

Synergism of trimethoprim and ciprofloxacin in vitro against clinical bacterial isolates.

Huovinen P, Wolfson JS, Hooper DC.

Eur J Clin Microbiol Infect Dis. 1992 Mar;11(3):255-7.

PMID:
1597204
4.

Overview of fluoroquinolone safety.

Wolfson JS, Hooper DC.

Am J Med. 1991 Dec 30;91(6A):153S-161S. Review.

PMID:
1767803
5.

A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus.

Trucksis M, Wolfson JS, Hooper DC.

J Bacteriol. 1991 Sep;173(18):5854-60.

6.

Pharmacokinetics of quinolones: newer aspects.

Wolfson JS, Hooper DC.

Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):267-74. Review.

PMID:
1864287
7.

Mode of action of the new quinolones: new data.

Hooper DC, Wolfson JS.

Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):223-31. Review.

PMID:
1650698
8.

Emerging resistance to fluoroquinolones in staphylococci: an alert.

Trucksis M, Hooper DC, Wolfson JS.

Ann Intern Med. 1991 Mar 1;114(5):424-6. No abstract available.

PMID:
1992885
9.

Fluoroquinolone antimicrobial agents.

Hooper DC, Wolfson JS.

N Engl J Med. 1991 Feb 7;324(6):384-94. Review. No abstract available.

PMID:
1987461
10.

Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents.

Wolfson JS, Hooper DC, McHugh GL, Bozza MA, Swartz MN.

Antimicrob Agents Chemother. 1990 Oct;34(10):1938-43.

12.

Comparative pharmacokinetics of ofloxacin and ciprofloxacin.

Wolfson JS, Hooper DC.

Am J Med. 1989 Dec 29;87(6C):31S-36S. Review.

PMID:
2690617
13.

Bacterial resistance to the quinolone antimicrobial agents.

Hooper DC, Wolfson JS.

Am J Med. 1989 Dec 29;87(6C):17S-23S. Review.

PMID:
2690616
14.

Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Wolfson JS.

Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1080-92. Review.

PMID:
2559848
15.

Value of new quinolones in the treatment and prophylaxis of infectious diseases: introductory remarks.

Wolfson JS, Murray BE.

Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1071-4. No abstract available.

PMID:
2559847
16.

Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Hooper DC, Wolfson JS.

Antimicrob Agents Chemother. 1989 Oct;33(10):1662-7. Review. No abstract available.

17.
18.

Fluoroquinolone antimicrobial agents.

Wolfson JS, Hooper DC.

Clin Microbiol Rev. 1989 Oct;2(4):378-424. Review.

20.

Bacterial resistance to quinolones: mechanisms and clinical importance.

Wolfson JS, Hooper DC.

Rev Infect Dis. 1989 Jul-Aug;11 Suppl 5:S960-8. Review.

PMID:
2549610
21.

Mode of action of the quinolone antimicrobial agents: review of recent information.

Hooper DC, Wolfson JS.

Rev Infect Dis. 1989 Jul-Aug;11 Suppl 5:S902-11. Review.

PMID:
2549608
22.

Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones.

Wolfson JS, Hooper DC, Shih DJ, McHugh GL, Swartz MN.

Antimicrob Agents Chemother. 1989 May;33(5):705-9.

23.

Adrenal crisis in the setting of high-dose ketoconazole therapy.

Khosla S, Wolfson JS, Demerjian Z, Godine JE.

Arch Intern Med. 1989 Apr;149(4):802-4.

PMID:
2705831
24.

Effects of inhibition of the B subunit of DNA gyrase on conjugation in Escherichia coli.

Hooper DC, Wolfson JS, Tung C, Souza KS, Swartz MN.

J Bacteriol. 1989 Apr;171(4):2235-7.

25.

Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.

Hooper DC, Wolfson JS, Souza KS, Ng EY, McHugh GL, Swartz MN.

Antimicrob Agents Chemother. 1989 Mar;33(3):283-90.

26.

Norfloxacin, ciprofloxacin, and ofloxacin: current clinical roles.

Hooper DC, Wolfson JS.

Curr Clin Top Infect Dis. 1989;10:194-240. Review. No abstract available.

PMID:
2679694
27.

Novobiocin-induced ultrastructural changes and antagonism of DNA synthesis in Trypanosoma cruzi amastigotes growing in cell-free medium.

Kerschmann RL, Wolfson JS, McHugh GL, Dickersin GR, Hooper DC, Swartz MN.

J Protozool. 1989 Jan-Feb;36(1):14-20.

PMID:
2651651
28.

Vancomycin-resistant gram-positive bacteria isolated from human sources.

Ruoff KL, Kuritzkes DR, Wolfson JS, Ferraro MJ.

J Clin Microbiol. 1988 Oct;26(10):2064-8.

29.

Endogenous active efflux of norfloxacin in susceptible Escherichia coli.

Cohen SP, Hooper DC, Wolfson JS, Souza KS, McMurry LM, Levy SB.

Antimicrob Agents Chemother. 1988 Aug;32(8):1187-91.

30.

Norfloxacin: a new targeted fluoroquinolone antimicrobial agent.

Wolfson JS, Hooper DC.

Ann Intern Med. 1988 Feb;108(2):238-51. Review.

PMID:
3277508
31.

Mode of action of the quinolone antimicrobial agents.

Hooper DC, Wolfson JS.

Rev Infect Dis. 1988 Jan-Feb;10 Suppl 1:S14-21. Review.

PMID:
2831608
32.

Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers.

Wolfson JS, Hooper DC, Ng EY, Souza KS, McHugh GL, Swartz MN.

Antimicrob Agents Chemother. 1987 Nov;31(11):1861-3.

33.

Dirofilaria ursi-like parasites acquired by humans in the northern United States and Canada: report of two cases and brief review.

Beaver PC, Wolfson JS, Waldron MA, Swartz MN, Evans GW, Adler J.

Am J Trop Med Hyg. 1987 Sep;37(2):357-62. Review.

PMID:
3310687
34.

Visualization of the mitochondrion-kinetoplast in viable Trypanosoma cruzi with rhodamine 123.

Wolfson JS, McHugh GL, Swartz MN, Ng EY, Hooper DC.

J Parasitol. 1987 Aug;73(4):866-9. No abstract available.

PMID:
2442343
35.

Mechanisms of action of and resistance to ciprofloxacin.

Hooper DC, Wolfson JS, Ng EY, Swartz MN.

Am J Med. 1987 Apr 27;82(4A):12-20. Review.

PMID:
3034057
36.

Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.

Hooper DC, Wolfson JS, Souza KS, Tung C, McHugh GL, Swartz MN.

Antimicrob Agents Chemother. 1986 Apr;29(4):639-44.

37.

Novobiocin antagonism of amastigotes of Trypanosoma cruzi growing in cell-free medium.

Pate PG, Wolfson JS, McHugh GL, Pan SC, Swartz MN.

Antimicrob Agents Chemother. 1986 Mar;29(3):426-31.

38.

The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Hooper DC, Wolfson JS.

Antimicrob Agents Chemother. 1985 Nov;28(5):716-21. Review. No abstract available.

39.

The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Wolfson JS, Hooper DC.

Antimicrob Agents Chemother. 1985 Oct;28(4):581-6. No abstract available.

40.

Knotting of DNA molecules isolated from deletion mutants of intact bacteriophage P4.

Wolfson JS, McHugh GL, Hooper DC, Swartz MN.

Nucleic Acids Res. 1985 Sep 25;13(18):6695-702.

41.

Cryptosporidiosis in immunocompetent patients.

Wolfson JS, Richter JM, Waldron MA, Weber DJ, McCarthy DM, Hopkins CC.

N Engl J Med. 1985 May 16;312(20):1278-82.

PMID:
4039408
42.

Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy.

Wolfson JS, Swartz MN.

N Engl J Med. 1985 Apr 11;312(15):968-75. Review. No abstract available.

PMID:
3883183
43.

Dermatologic manifestations of infections in immunocompromised patients.

Wolfson JS, Sober AJ, Rubin RH.

Medicine (Baltimore). 1985 Mar;64(2):115-33.

PMID:
3974441
44.

Pasteurella multocida infections. Report of 34 cases and review of the literature.

Weber DJ, Wolfson JS, Swartz MN, Hooper DC.

Medicine (Baltimore). 1984 May;63(3):133-54. Review.

PMID:
6371440
45.

Elimination of plasmid pMG110 from Escherichia coli by novobiocin and other inhibitors of DNA gyrase.

Hooper DC, Wolfson JS, McHugh GL, Swartz MD, Tung C, Swartz MN.

Antimicrob Agents Chemother. 1984 May;25(5):586-90.

46.

An association between cryptosporidium and giardia in stool.

Wolfson JS, Hopkins CC, Weber DJ, Richter JM, Waldron MA, McCarthy DM.

N Engl J Med. 1984 Mar 22;310(12):788. No abstract available.

PMID:
6700661
47.

Novobiocin-induced elimination of F'lac and mini-F plasmids from Escherichia coli.

Wolfson JS, Hooper DC, Swartz MN, Swartz MD, McHugh GL.

J Bacteriol. 1983 Dec;156(3):1165-70.

48.

Rapid method for screening large numbers of Escherichia coli colonies for production of plasmid-mediated beta-lactamases.

Wolfson JS, Hooper DC, Swartz MN, Swartz MD, McHugh GL.

Antimicrob Agents Chemother. 1983 Feb;23(2):308-12.

49.

Dermatologic manifestations of infection in the compromised host.

Wolfson JS, Sober AJ, Rubin RH.

Annu Rev Med. 1983;34:205-17. Review.

PMID:
6344755
50.

Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth.

Hooper DC, Wolfson JS, McHugh GL, Winters MB, Swartz MN.

Antimicrob Agents Chemother. 1982 Oct;22(4):662-71.

Supplemental Content

Loading ...
Support Center